Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Merestinib Bioavailability
NCT02779738Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of merestinib in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration (Cmax) for Merestinib and Area Under The Concentration Curve AUC(0-∞) for Merestinib. Started May 2016; status: completed.
02
Drugs
merestinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02779738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779738.